MS and Demyelinating Disorders

Patients with high levels of neurofilament light at baseline had an increased risk of developing new T2 lesions and of experiencing a new clinical relapse in the follow-up period, but not of EDSS progression.

Dr DeLuca provides an overview of changes in cognition and brain volume loss in patients with multiple sclerosis.

Through dedicated research into biomarker discovery and patient care, the neuroimmunology laboratory at Mayo Clinic has paved a new way of life for those with autoimmune disorders.

Dr Heidi Crayton reviews treatment efficacy and safety considerations for conventional and novel treatment options for patients with relapsing-remitting multiple sclerosis.

Heidi Crayton, MD, shares her thoughts surrounding treatment initiation and management considerations in patients with relapsing-remitting multiple sclerosis.

Experts in neurology discuss the multiple ways in which cognitive decline can present in their patients with multiple sclerosis and highlight how they assess for it.

Heidi Crayton, MD; Jacqueline Nicholas, MD; and Flavia Nelson, MD, provide an overview of multiple sclerosis shedding light on the clinical course of disease.

Ocrelizumab (Ocrevus; Genentech), an anti-CD20 treatment FDA-approved for progressive MS, was shown to reduce thalamic volume loss, with even greater outcomes when initiated earlier.

The NeurologyLive® team has compiled a roundup of our discussions with leaders in the multiple sclerosis field following the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

The head of the MS center at University Hospital Basel provided insight on the role of BTK inhibitors and how the multiple sclerosis community views the potential of neurofilament light as a key biomarker of neurodegeneration. [WATCH TIME: 3 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

At least 2 weeks following Evusheld injection, all 18 patients included in the cohort had the highest level of antibody response.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 24, 2022.

The associate neurologist at Brigham and Women’s Hospital provided insight on the current state of promising targets in progressive MS and why anti-CD3 therapy might be a new consideration for future trials. [WATCH TIME: 2 minutes]

Expert neurologists emphasize the importance of conversations around patient lifestyle, mental health, and comorbid conditions as keys to improve care for MS.

Barry A. Hendin, MD; Regina Berkovich, MD, PhD; and Ahmed Z. Obeidat, MD, PhD, explore the role of biomarkers, precision medicine, and repair mechanisms to improve treatment of MS going forward.

Regina Berkovich, MD, PhD, and Barry A. Hendin, MD, review potential use of BTK inhibitors in the treatment of MS.

A trio of experts in multiple sclerosis exchanges their thoughts on the use of the sphingosine-1 phosphate modulating class of medicines in treating the disease. [WATCH TIME: 3 minutes]

A trio of experts in multiple sclerosis exchanges their thoughts on the gains that have been made in the understanding of the progressive phases of the disease. [WATCH TIME: 3 minutes]

More than $5.2 million in new, unused DMTs were collected from patients with MS over the course of 1 year—from only 1 neuroimmunologist.

A trio of experts in multiple sclerosis exchanges their thoughts on the importance of patient-reported outcomes in the management of patients with the disease. [WATCH TIME: 3 minutes]

The associate neurologist at Brigham and Women’s Hospital provided background on a new case study of a patient with progressive MS who showed positive outcomes using foralumab, an anti-CD3 targeting agent. [WATCH TIME: 3 minutes]

The president and chief executive officer of Mapi Pharma discussed the positive phase 2 findings of a new formulation of glatiramer acetate to treat progressive forms of MS, as well as the long-term plans for the drug. [WATCH TIME: 5 minutes]

After 24 weeks of treatment, the adjusted mean annualized relapse rates were 0.53 with placebo vs 0.39 and 0.48 for the 30- and 45-mg groups of IMU-838.